Hormone-refractory prostate cancer
RecruitingStudy Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy and Chemotherapy
Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy and Chemotherapy
- Disease:Hormone-refractory prostate cancer
- Substances:Abiraterone AcetateDexamethasone+9
Hungary- Participants:18–64 years · 65+ years
- Substances:Abiraterone Acetate
- Sponsor:Merck Sharp & Dohme LLC











